I agree with Morgan 628 and other long Fools on this one. Another medical growth story trading like a value stock. Strong position in the oncology market; consistent EPS growth over the last decade; little debt with mid-teen forward p/e about half of… More
Varian may have current market share but their technology has been rendered obsolete by the commercial introduction of Accuray's CyberKnife. This is why Varian's sales have flattened out. Even Varian's hack analyst Amit Hazan admits as much in his… More